Literature DB >> 35001938

Change Point Inference in the Presence of Missing Covariates for Principal Surrogate Evaluation in Vaccine Trials.

Tao Yang1, Ying Huang1, Youyi Fong1.   

Abstract

We consider the use of threshold-based regression models for evaluating immune response biomarkers as principal surrogate markers of a vaccine's protective effect. Threshold-based regression models, which allow the relationship between a clinical outcome and a covariate to change dramatically across a threshold value in the covariate, have been studied by various authors under fully observed data. Limited research, however, has examined these models in the presence of missing covariates, such as the counterfactual potential immune responses of a participant in the placebo arm of a standard vaccine trial had s/he been assigned to the vaccine arm instead. Based on a hinge model for a threshold effect of the principal surrogate on vaccine efficacy, we develop a regression methodology that consists of two components: (1) The estimated likelihood method is employed to handle missing potential outcomes, and (2) a penalty is imposed on the estimated likelihood to ensure satisfactory finite sample performance. We develop a method that allows joint estimation of all model parameters as well as a two-step method that separates the estimation of the threshold parameter from the rest of the parameters. Stable iterative algorithms are developed to implement the two methods and the asymptotic properties of the proposed estimators are established. In simulation studies, the proposed estimators are shown to have satisfactory finite sample performance. The proposed methods are applied to analyze a real dataset collected from dengue vaccine efficacy trials to predict how vaccine efficacy varies with an individual's potential immune response if receiving vaccine.

Entities:  

Keywords:  Hinge threshold regression modeling; Missing potential outcomes; Penalized estimated likelihood; Principal surrogate; Vaccine efficacy

Year:  2020        PMID: 35001938      PMCID: PMC8741149          DOI: 10.1093/biomet/asaa100

Source DB:  PubMed          Journal:  Biometrika        ISSN: 0006-3444            Impact factor:   2.445


  17 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

3.  Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Authors:  Leah C Katzelnick; Magelda Montoya; Lionel Gresh; Angel Balmaseda; Eva Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

4.  Augmented designs to assess immune response in vaccine trials.

Authors:  Dean Follmann
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

5.  Evaluating candidate principal surrogate endpoints.

Authors:  Peter B Gilbert; Michael G Hudgens
Journal:  Biometrics       Date:  2008-03-24       Impact factor: 2.571

6.  A Z-theorem with Estimated Nuisance Parameters and Correction Note for 'Weighted Likelihood for Semiparametric Models and Two-phase Stratified Samples, with Application to Cox Regression'

Authors:  Norman E Breslow; Jon A Wellner
Journal:  Scand Stat Theory Appl       Date:  2008-03-01       Impact factor: 1.396

7.  Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

Authors:  Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

8.  Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling.

Authors:  Ying Huang
Journal:  Biometrics       Date:  2017-06-26       Impact factor: 2.571

9.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

Authors:  Maria Rosario Capeding; Ngoc Huu Tran; Sri Rezeki S Hadinegoro; Hussain Imam H J Muhammad Ismail; Tawee Chotpitayasunondh; Mary Noreen Chua; Chan Quang Luong; Kusnandi Rusmil; Dewa Nyoman Wirawan; Revathy Nallusamy; Punnee Pitisuttithum; Usa Thisyakorn; In-Kyu Yoon; Diane van der Vliet; Edith Langevin; Thelma Laot; Yanee Hutagalung; Carina Frago; Mark Boaz; T Anh Wartel; Nadia G Tornieporth; Melanie Saville; Alain Bouckenooghe
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

10.  Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America.

Authors:  Lindsay N Carpp; Youyi Fong; Matthew Bonaparte; Zoe Moodie; Michal Juraska; Ying Huang; Brenda Price; Yingying Zhuang; Jason Shao; Lingyi Zheng; Laurent Chambonneau; Robert Small; Saranya Sridhar; Carlos A DiazGranados; Peter B Gilbert
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.